FiercePharma3d
Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Medscape1mon
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal ...
MedCity News27d
AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer
Last week, the FDA accepted an application seeking approval of the ADC for EGFR-mutated non-small cell lung cancer. A regulatory decision in this indication is expected in the third quarter of ...
Pharmabiz17h
OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer
OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer: Princeton, New Jersey Saturday, February 15, 2025, 15:00 ...
Reuters1mon
US FDA approves AstraZeneca's drug for breast cancer
AstraZeneca and Daiichi's first co-developed ADC, Enhertu, was first approved by the FDA in 2019 for a type of ... Citigroup 11:15 PM UTC · Updated ago Sustainable Finance & Reportingcategory ...
Nasdaq26d
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug ...
BioWorld26d
FDA approves Daiichi Sankyo’s Trop-2 ADC for breast cancer
Marking the second global approval after Japan, the U.S. FDA has approved Datroway (datopotamab deruxtecan), a trophoblast cell surface antigen 2-directed antibody-drug conjugate (ADC) from Daiichi ...